Treatment options in Alzheimer's disease: Maximizing benefit, managing expectations

被引:103
作者
Farlow, Martin R. [1 ]
Miller, Michael L. [2 ]
Pejovic, Vojislav [2 ]
机构
[1] Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA
[2] Prescott Med Commun Grp, Chicago, IL USA
关键词
Alzheimer's disease; cholinesterase inhibitors; Memantine; pharmacotherapy; combination therapy; antioxidants; Ginkgo biloba;
D O I
10.1159/000122962
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Alzheimer's disease ( AD) is becoming an increasingly heavy burden on the society of developed countries, and physicians now face the challenge of providing efficient treatment regimens to an ever-higher number of individuals affected by the disease. Currently approved anti-AD therapies - the cholinesterase inhibitors and the N-methyl-D-aspartate receptor antagonist memantine-offer modest symptomatic relief, which can be enhanced using combination therapy with both classes of drugs. Additionally, alternative therapies such as nonsteroidal anti-inflammatory drugs, vitamin E, selegiline, Ginkgo biloba extracts, estrogens, and statins, as well as behavioral and lifestyle changes, have been explored as therapeutic options. Until a therapy is developed that can prevent or reverse the disease, the optimal goal for effective AD management is to develop a treatment regimen that will yield maximum benefits for individual patients across multiple domains, including cognition, daily functioning, and behavior, and to provide realistic expectations for patients and caregivers throughout the course of the disease. This review provides a basic overview of approved AD therapies, discusses some pharmacologic and nonpharmacologic treatment strategies that are currently being investigated, and offers suggestions for optimizing treatment to fit the needs of individual patients. Copyright (c) 2008 S. Karger AG, Basel.
引用
收藏
页码:408 / 422
页数:15
相关论文
共 182 条
  • [51] Mild cognitive impairment
    Gauthier, S
    Reisberg, B
    Zaudig, M
    Petersen, RC
    Ritchie, K
    Broich, K
    Belleville, S
    Brodaty, H
    Bennett, D
    Chertkow, H
    Cummings, JL
    de Leon, M
    Feldman, H
    Ganguli, M
    Hampel, H
    Scheltens, P
    Tierney, MC
    Whitehouse, P
    Winblad, B
    [J]. LANCET, 2006, 367 (9518) : 1262 - 1270
  • [52] Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors
    Gauthier, S
    Emre, M
    Farlow, MR
    Bullock, R
    Grossberg, GT
    Potkin, SG
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2003, 19 (08) : 707 - 714
  • [53] Cholinesterase inhibitors: new roles and therapeutic alternatives
    Giacobini, E
    [J]. PHARMACOLOGICAL RESEARCH, 2004, 50 (04) : 433 - 440
  • [54] Cholinesterases: New roles in brain function and in Alzheimer's disease
    Giacobini, E
    [J]. NEUROCHEMICAL RESEARCH, 2003, 28 (3-4) : 515 - 522
  • [55] Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease
    Gobburu, JVS
    Tammara, V
    Lesko, L
    Jhee, SS
    Sramek, JJ
    Cutler, NR
    Yuan, RH
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (10) : 1082 - 1090
  • [56] GomezIsla T, 1996, J NEUROSCI, V16, P4491
  • [57] Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease
    Grossberg, GT
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (10) : 1631 - 1639
  • [58] Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy
    Hartmann, S
    Möbius, HJ
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2003, 18 (02) : 81 - 85
  • [59] Alzheimer disease in the US population - Prevalence estimates using the 2000 census
    Hebert, LE
    Scherr, PA
    Bienias, JL
    Bennett, DA
    Evans, DA
    [J]. ARCHIVES OF NEUROLOGY, 2003, 60 (08) : 1119 - 1122
  • [60] Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050
    Hebert, LE
    Beckett, LA
    Scherr, PA
    Evans, DA
    [J]. ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2001, 15 (04) : 169 - 173